Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -48.35% is 36% above its 5-year average of -75.48%, near the high end of its 5-year range (-125.14%–-20.30%).
52.99% above its 12-month average of -102.84%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.73%.
RETURN ON ASSETS (ROA)
-48.35%
RETURN ON ASSETS (ROA) AVG TTM
-102.84%
RETURN ON ASSETS (ROA) AVG 3Y
-97.55%
RETURN ON ASSETS (ROA) AVG 5Y
-75.48%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+52.99%
CURRENT VS 3Y AVG
+50.44%
CURRENT VS 5Y AVG
+35.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.24%
median of 495 covered companies
CURRENT VS SECTOR MEDIAN
-84.26%
vs the sector median at left
Damora Therapeutics, Inc.
Market Cap
$1.24B
Return on Assets (ROA)
-48.35%
TTM Avg
-102.84%
3Y Avg
-97.55%
5Y Avg
-75.48%
Market Cap
$1.22B
Return on Assets (ROA)
-0.46%
TTM Avg
-2.95%
3Y Avg
-4.25%
5Y Avg
-4.39%
Market Cap
$1.21B
Return on Assets (ROA)
5.91%
TTM Avg
1.36%
3Y Avg
-4.42%
5Y Avg
-8.30%
Market Cap
$1.20B
Return on Assets (ROA)
-57.23%
TTM Avg
-57.23%
3Y Avg
-57.23%
5Y Avg
-57.23%
Market Cap
$1.16B
Return on Assets (ROA)
0.69%
TTM Avg
1.67%
3Y Avg
0.18%
5Y Avg
-3.47%
Market Cap
$1.33B
Return on Assets (ROA)
-41.48%
TTM Avg
-39.59%
3Y Avg
-35.47%
5Y Avg
-52.36%
Market Cap
$1.34B
Return on Assets (ROA)
-68.96%
TTM Avg
-38.41%
3Y Avg
-33.02%
5Y Avg
-35.57%
Market Cap
$1.14B
Return on Assets (ROA)
-8.93%
TTM Avg
-2.89%
3Y Avg
-5.64%
5Y Avg
-7.78%
Market Cap
$1.14B
Return on Assets (ROA)
-36.19%
TTM Avg
-21.98%
3Y Avg
-157.70%
5Y Avg
-157.70%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.24B | -48.35% | -102.84% | -97.55% | -75.48% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | -0.46% | -2.95% | -4.25% | -4.39% |
| Cronos Group Inc. (CRON)vs › | $1.21B | 5.91% | 1.36% | -4.42% | -8.30% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | -57.23% | -57.23% | -57.23% | -57.23% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.69% | 1.67% | 0.18% | -3.47% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | -41.48% | -39.59% | -35.47% | -52.36% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.34B | -68.96% | -38.41% | -33.02% | -35.57% |
| Harrow Health, Inc. (HROW)vs › | $1.14B | -8.93% | -2.89% | -5.64% | -7.78% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.14B | -36.19% | -21.98% | -157.70% | -157.70% |
| Kardigan, Inc. (KARD)vs › | $1.36B | -49.10% | -49.10% | -49.10% | -49.10% |
ROA
-48.4%
ROE
-50.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -80.54% |
| 2024-12-31 | -125.14% |
| 2023-12-31 | -100.32% |
| 2022-12-31 | -84.20% |
| 2021-12-31 | -42.35% |
| 2020-12-31 | -20.30% |
| 2019-12-31 | -64.49% |
| 2018-12-31 | -45.21% |
